Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S291-S294 , March 2004

Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation

  • T.Casanovas Taltavull

      Affiliations

    • Liver Transplant Unit, Hospital Universitario de Belvitge, L'Hospitalet de Llobregat, Barcelona, Spain
    • Corresponding Author InformationAddress reprint requests to Dr. Teresa Casanovas Taltavull, Liver Transplant Unit Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat 08907, Barcelona, Spain.

References 

  1. Prieto M, Clemente G, Casafont F, et al.  Documento de consenso de indicaciones de trasplante hepático. Gastroenterol Hepatol. 2003;26:355
  2. Jaurrieta E, Casais L, Figueras J, et al.  Análisis de 500 transplantes hepáticos en el Hospital de Bellvitge. Med Clin (Barc). 2000;115:521
  3. Figueras J, Casanovas T, Rafecas A, et al.  Quality of life after liver transplant. Med Clin (Barc). 1989;93:207
  4. Casanovas Taltavull T, Vallejo G, Herdman M, et al.  Transcultural adaptation of the Liver Disease Quality of Life Instrument (LDQOL 1.0) for its use in the Spanish population. Gastroenterol Hepatol. 2003;26:234
  5. Calmus Y, Soldevila-Pico I, Jaurrieta EJ, et al.  Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002;8:219
  6. Xiol X, Castellote J, Vázquez S, et al.  Prospective randomized trial on the safety and efficacy of steroid free immunosuppression after liver transplantation. Preliminary results. J Hepatol. 2003;38(suppl 2):A154
  7. Adams DH, Liu QI. FK 506 inhibits lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. Hepatology. 1996;23:1476
  8. Nelson DR, Soldevila-Pico C, Reed A, et al.  Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001;7:1064
  9. Zamanskaite A. FK 506 and CsA differ in their effect on intracellular cytokine expression following kidney transplantation. Transplant Proc. 2001;33:1046
  10. Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis. 2003;7:107
  11. Winkler M. Cyclosporin as baseline immunosuppression in solid organ transplantation. BioDrugs. 2000;14:185
  12. Berenguer M, Ferrell L, Watson J, et al.  HCV-related fibrosis progression following liver transplantation (increase in recent years). J Hepatol. 2000;32:673
  13. Levy G, Burra P, Cavallari A, et al.  Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2 hours post-dose levels (C2). Transplantation. 2002;73:953
  14. Santoyo J, Suarez MA, Perez-Daga JA, et al.  Efficacy of C2 monitoring of Cyclosporine Neoral in adult liver transplantation (a comparative study). Transplant Proc. 2001;33:3096
  15. Rosen HR. Hepatitis B and C in the liver transplant recipient (current understanding and treatment). Liver Transplantation. 2001;7(Suppl 1):S87
  16. Gane EJ, Portmann BC, Naoumov NV, et al.  Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815
  17. Prieto M, Berenguer M, Rayon M, et al.  High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation (relationship with rejection episodes). Hepatology. 1999;29:250
  18. Samuel D, Bizollon T, Feray, et al: Interferon alfa 2b plus Ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124:642, 2003.
  19. Bizollon T, Palazzo U, Ducerf C, et al.  Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 1997;26:500
  20. Scheuer PJ. Classification of chronic viral hepatitis (a need for a reassessment). J Hepatol. 1991;13:372
  21. Casanovas Taltavull T, Ramos E, Serrano T, et al.  Pilot study with the combination of interferon alfa and ribavirin for recurrent post-liver transplantation hepatitis C. Causes of treatment failure in two different populations. Hepatology. 2001;34:A477
  22. Casanovas Taltavull T, Ramos E, Serrano T, et al.  Long term histological and virological follow-up of a selected group of liver transplanted patients with hepatitis C recidive who were treated with interferon alfa and ribavirin. Hepatology. 2002;36:A58
  23. Ghobrial RM, Farmer DG, Baquerizo A, et al.  Orthotopic liver transplantation for hepatitis C (outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience). Ann Surg. 1999;229:824
  24. Kugelmas M, Osgood MJ, Trotter JF, et al: Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellularrejection. Liver Transpl 9:1159, 2003
  25. Kakumu S, Takayanagi M, Iwata K, et al.  Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol. 1997;12:62
  26. Inoue K, Sekiyama K, Yamada M, et al.  Combined interferon alfa 2b and cyclosporin A in the treatment of chronic hepatitis C (controlled trial). J Gastroenterol. 2003;38:567
  27. Samuel D, Duclos Vallee JCh, Teicher E, et al.  Liver transplantation in patients with HIV infection. J Hepatol. 2003;39:3
  28. Stock PC, Roland ME, Carlson L, et al.  Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76:370
  29. Neff GW, Bonham A, Tzakis AG, et al.  Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239

PII: S0041-1345(03)01343-5

doi: 10.1016/j.transproceed.2003.12.032

Transplantation Proceedings
Volume 36, Issue 2, Supplement , Pages S291-S294 , March 2004

Article Tools